Crystal Bio Solutions built its business around a stubborn truth of drug development: the clinical decision can be only as good as the assay beneath it. Its new bet is to keep the test, the model, and the regulatory argument in the same conversation.
For nearly four decades, Ampersand Capital Partners has skipped the lottery of drug discovery and quietly backed the companies that make the drug discovery possible. In May 2026 it closed a $1.5 billion fund in a single day.